Vanda Submits NDA For Antipsychotic Iloperidone

Firm says if schizophrenia treatment is approved, a favorable safety profile will differentiate the product from competitors.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet